UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Omnicell, Inc. (NASDAQ:OMCL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 22.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 119,181 shares of the company's stock after buying an additional 21,847 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.26% of Omnicell worth $5,306,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. KBC Group NV lifted its holdings in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock worth $92,000 after acquiring an additional 778 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Omnicell by 93.3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after purchasing an additional 699,925 shares during the last quarter. Empowered Funds LLC bought a new stake in Omnicell in the fourth quarter worth about $388,000. Shaker Investments LLC OH purchased a new position in shares of Omnicell during the fourth quarter valued at approximately $550,000. Finally, Van ECK Associates Corp grew its stake in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after buying an additional 315 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Omnicell Stock Up 0.4%

Shares of OMCL stock traded up $0.13 during mid-day trading on Friday, hitting $31.00. The stock had a trading volume of 456,397 shares, compared to its average volume of 571,971. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm's 50-day moving average is $30.09 and its two-hundred day moving average is $37.65. The firm has a market capitalization of $1.45 billion, a P/E ratio of 114.82, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. During the same period in the prior year, the firm earned $0.03 earnings per share. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year. On average, analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Bank of America raised their price target on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Wall Street Zen upgraded Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, May 20th. Benchmark cut their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $44.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.